A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs LY 3127804 (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
  • Indications Gastric cancer; Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
    • 31 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top